Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Generalized eruptive syringoma

Yuichiro Tsunemi, Hironobu Ihn, Hidehisa Saeki

    Pediatric Dermatology
    |September 30, 2005
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Characterization of Prurigo Nodules in Adults With Moderate-To-Severe Atopic Dermatitis in Japan: A 2-Year Observational Study.

    The Journal of dermatology·2026
    Same author

    Real-World Effectiveness of Tildrakizumab in Japanese Patients With Psoriasis: Analyses Stratified by Prior Systemic Therapy, Maintenance of Early Responses, and Achievement of Delayed Responses.

    The Journal of dermatology·2026
    Same author

    New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review.

    Dermatology and therapy·2026
    Same author

    Three-year real-world outcomes of upadacitinib treatment for atopic dermatitis: Systemic therapy-naïve versus -experienced patients.

    Journal of the American Academy of Dermatology·2026
    Same author

    Real-World Maintenance of Remission in Atopic Dermatitis Patients With Upadacitinib: A Multicenter Retrospective Study in Japan (ROADMAP Study).

    The Journal of dermatology·2026
    Same author

    Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years).

    European journal of dermatology : EJD·2026